Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: an international validation study.
Lung adenocarcinoma (AD) represents a predominant type of lung cancer demonstrating significant morphologic and molecular heterogeneity. We sought to understand this heterogeneity by utilizing gene expression analyses of 432 AD samples and examining associations between 27 known cancer-related pathw...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2010-07-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20661423/?tool=EBI |
| _version_ | 1818404453337792512 |
|---|---|
| author | Christopher M Bryant Daniel L Albertus Sinae Kim Guoan Chen Christian Brambilla Mickael Guedj Chinatsu Arima William D Travis Yasushi Yatabe Takashi Takahashi Elisabeth Brambilla David G Beer |
| author_facet | Christopher M Bryant Daniel L Albertus Sinae Kim Guoan Chen Christian Brambilla Mickael Guedj Chinatsu Arima William D Travis Yasushi Yatabe Takashi Takahashi Elisabeth Brambilla David G Beer |
| author_sort | Christopher M Bryant |
| collection | DOAJ |
| description | Lung adenocarcinoma (AD) represents a predominant type of lung cancer demonstrating significant morphologic and molecular heterogeneity. We sought to understand this heterogeneity by utilizing gene expression analyses of 432 AD samples and examining associations between 27 known cancer-related pathways and the AD subtype, clinical characteristics and patient survival. Unsupervised clustering of AD and gene expression enrichment analysis reveals that cell proliferation is the most important pathway separating tumors into subgroups. Further, AD with increased cell proliferation demonstrate significantly poorer outcome and an increased solid AD subtype component. Additionally, we find that tumors with any solid component have decreased survival as compared to tumors without a solid component. These results lead to the potential to use a relatively simple pathological examination of a tumor in order to determine its aggressiveness and the patient's prognosis. Additional results suggest the ability to use a similar approach to determine a patient's sensitivity to targeted treatment. We then demonstrated the consistency of these findings using two independent AD cohorts from Asia (N = 87) and Europe (N = 89) using the identical analytic procedures. |
| first_indexed | 2024-12-14T08:40:23Z |
| format | Article |
| id | doaj.art-ba78ce948c7a4f06b2e20da12c7ea872 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-14T08:40:23Z |
| publishDate | 2010-07-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-ba78ce948c7a4f06b2e20da12c7ea8722022-12-21T23:09:18ZengPublic Library of Science (PLoS)PLoS ONE1932-62032010-07-0157e1171210.1371/journal.pone.0011712Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: an international validation study.Christopher M BryantDaniel L AlbertusSinae KimGuoan ChenChristian BrambillaMickael GuedjChinatsu ArimaWilliam D TravisYasushi YatabeTakashi TakahashiElisabeth BrambillaDavid G BeerLung adenocarcinoma (AD) represents a predominant type of lung cancer demonstrating significant morphologic and molecular heterogeneity. We sought to understand this heterogeneity by utilizing gene expression analyses of 432 AD samples and examining associations between 27 known cancer-related pathways and the AD subtype, clinical characteristics and patient survival. Unsupervised clustering of AD and gene expression enrichment analysis reveals that cell proliferation is the most important pathway separating tumors into subgroups. Further, AD with increased cell proliferation demonstrate significantly poorer outcome and an increased solid AD subtype component. Additionally, we find that tumors with any solid component have decreased survival as compared to tumors without a solid component. These results lead to the potential to use a relatively simple pathological examination of a tumor in order to determine its aggressiveness and the patient's prognosis. Additional results suggest the ability to use a similar approach to determine a patient's sensitivity to targeted treatment. We then demonstrated the consistency of these findings using two independent AD cohorts from Asia (N = 87) and Europe (N = 89) using the identical analytic procedures.https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20661423/?tool=EBI |
| spellingShingle | Christopher M Bryant Daniel L Albertus Sinae Kim Guoan Chen Christian Brambilla Mickael Guedj Chinatsu Arima William D Travis Yasushi Yatabe Takashi Takahashi Elisabeth Brambilla David G Beer Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: an international validation study. PLoS ONE |
| title | Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: an international validation study. |
| title_full | Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: an international validation study. |
| title_fullStr | Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: an international validation study. |
| title_full_unstemmed | Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: an international validation study. |
| title_short | Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: an international validation study. |
| title_sort | clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways an international validation study |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20661423/?tool=EBI |
| work_keys_str_mv | AT christophermbryant clinicallyrelevantcharacterizationoflungadenocarcinomasubtypesbasedoncellularpathwaysaninternationalvalidationstudy AT daniellalbertus clinicallyrelevantcharacterizationoflungadenocarcinomasubtypesbasedoncellularpathwaysaninternationalvalidationstudy AT sinaekim clinicallyrelevantcharacterizationoflungadenocarcinomasubtypesbasedoncellularpathwaysaninternationalvalidationstudy AT guoanchen clinicallyrelevantcharacterizationoflungadenocarcinomasubtypesbasedoncellularpathwaysaninternationalvalidationstudy AT christianbrambilla clinicallyrelevantcharacterizationoflungadenocarcinomasubtypesbasedoncellularpathwaysaninternationalvalidationstudy AT mickaelguedj clinicallyrelevantcharacterizationoflungadenocarcinomasubtypesbasedoncellularpathwaysaninternationalvalidationstudy AT chinatsuarima clinicallyrelevantcharacterizationoflungadenocarcinomasubtypesbasedoncellularpathwaysaninternationalvalidationstudy AT williamdtravis clinicallyrelevantcharacterizationoflungadenocarcinomasubtypesbasedoncellularpathwaysaninternationalvalidationstudy AT yasushiyatabe clinicallyrelevantcharacterizationoflungadenocarcinomasubtypesbasedoncellularpathwaysaninternationalvalidationstudy AT takashitakahashi clinicallyrelevantcharacterizationoflungadenocarcinomasubtypesbasedoncellularpathwaysaninternationalvalidationstudy AT elisabethbrambilla clinicallyrelevantcharacterizationoflungadenocarcinomasubtypesbasedoncellularpathwaysaninternationalvalidationstudy AT davidgbeer clinicallyrelevantcharacterizationoflungadenocarcinomasubtypesbasedoncellularpathwaysaninternationalvalidationstudy |